Breaking news

2025 Sets a Positive Trend for Cyprus Real Estate

The real estate market in Cyprus has surged forward in 2025, marking a significant 15% increase in property sales compared to the previous year. This remarkable growth in the first quarter is highlighted by the 4,137 sale documents filed, as per reports from the Registration Council of Real Estate Agents.

While there was a slight decrease of 2.9% in transaction volume, the sales value saw a robust increase of 15%, surpassing €1.1 billion annually. This promising start to the year reflects sustained demand and better alignment of supply to market needs.

Insights from Regional Markets

Limassol continues to dominate the market, boasting the highest value transfer at €428.7 million and leading in documentation volume with 1,295 sale filings. Additionally, the city recorded 1,203 transaction volumes, underscoring strong investment activities.

In Nicosia, stability reigns with 1,304 transactions valued at €283.5 million. The city attracted 932 new sale documents, reflecting keen interest in fresh developments.

The momentum from previous years carries on in Paphos, with 811 transfers totaling €199 million. This shows lively activity in property purchase, fueled chiefly by international buyers.

Larnaca saw €154 million in transactions from 843 property transfers. The sale documents numbered 910, indicating rising demand bolstered by ongoing investments, as featured in Desalination Breakthrough: Addressing Water Shortages in Cyprus.

Though the Famagusta region ranked lowest with €48 million and 251 transfers, the growth trend persists. The 171 sale documents filed signal an appeal through lower prices and tourism-driven development.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
eCredo
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter